There's been intense effort over the past several years to try to determine the best regulatory approach when it comes to mHealth technology. Thousands of hours have been spent in meetings, conferences, hearings and conversations, all in a quest to figure out how best to protect patients, foster innovation among developers and creators, and not hurt a burgeoning industry that could potentially be greater than the PC revolution. Much of it has been focused on figuring out how to wedge mHealth tools into regulatory parameters already in place within the U.S. Food and Drug Administration, the Federal Trade Commission, and dozens of other federal and state agencies tasked with making sure what's in the market doesn't hurt the consumer, protecting data privacy and securing information. But what if we stopped trying to wedge and just started from scratch in crafting a regulatory body specifically for mHealth?
The U.S. Food and Drug Administration should be given robust oversight regarding mobile healthcare products and technology, states an article published July 24 in the New England Journal of Medicine. Such a role, authors Nathan Cortez, J.D., I. Glenn Cohen and Aaron S. Kesselheim, M.P.H. say, will not hinder innovation but may be a necessary linchpin for safe mHealth tools, devices and platforms.
Concerns about overutilization of imaging, its appropriateness in all cases, and its costs in terms of healthcare dollars and exposure to ionizing radiation has led to an increasing emphasis on clinical decision support. In this special report, FierceMedicalImaging explores the importance of CDS in radiology. We talk with healthcare professionals about what's necessary to increase physician adoption and how such tools can be improved. Full Report
Ten years after its creation during the Bush administration, the Office of the National Coordinator for Health IT finds itself squarely in the crosshairs of federal lawmakers uncertain of the...
Apple and IBM are forging a global strategic partnership to transform business using mobile technology. A big chunk of that strategy is aimed at the healthcare sector, specifically the mobile healthcare segment.
This is what we know--colorectal cancer screening works. Despite this, screening rates remain problematic. According to the Centers for Disease Control and Prevention, about one in three adults ages 50 to 75, haven't been tested for colorectal cancer as recommended by the United States Preventive Services Task Force.
As Google's Glass offering already is making headlines thanks to various mHealth pilots and initiatives, some industry experts remain wary of such efforts due to security issues
In an exclusive interview with FierceHealthIT, health attorney Brad Thompson of Epstein Becker Green elaborates on what potential legislation for CDS could mean.
In their efforts to secure patient data, hospital executives continue to worry about mobile devices--and are employing technology to help. But they acknowledge that the human factor remains the trickiest part of data security. Special Report
How should hospitals go about deciding whether to acquire a practice? How do they know which practices will be a good fit? And what are the risks versus the potential rewards?